STOCK TITAN
  1. Home
  2. Sec-filings
  3. KZIA
  4. [Form 3/A] KAZIA THERAPEUTICS LTD Amended Initial Statement of Beneficial Ownership

Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3/A

Rhea-AI Filing Summary

Kazia Therapeutics Ltd chief executive John E. Friend II reports his holdings of an American Depositary Share (ADS) option covering 30,000 ADSs. The ADS option was granted on July 22, 2024 at an exercise price of $18.85 per ADS and expires on July 22, 2027. It vests in equal quarterly installments over three years beginning April 22, 2024, contingent on continued service. This amended Form 3 corrects the exercise price of the previously reported ADS option.

Positive

  • None.

Negative

  • None.
Insider Friend John E. II
Role Chief Executive Officer
Type Security Shares Price Value
holding American Depositary Share Option (Right to Buy) -- -- --
Holdings After Transaction: American Depositary Share Option (Right to Buy) — 30,000 shares (Direct)
Footnotes (4)
  1. F1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 22, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 22, 2024.
  2. F2. Each ADS option is convertible into ADSs upon exercise.
  3. F3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
  4. F4. This Form 3/A is being filed to correct the exercise price of the ADS option granted on July 22, 2024.
ADS option underlying shares 30,000 ADSs Underlying American Depositary Shares for CEO option holding
Exercise price $18.85 per ADS Corrected exercise price for ADS option granted July 22, 2024
Option expiration date July 22, 2027 Expiration of American Depositary Share option
Vesting schedule 3 years, quarterly Equal quarterly installments starting April 22, 2024
ADS to ordinary share ratio 1 ADS : 500 ordinary shares Conversion relationship between ADSs and ordinary shares
American Depositary Shares financial
"Each ADS may be represented by 500 ordinary shares of the Issuer"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
ADS option financial
"The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest"
exercise price financial
"This Form 3/A is being filed to correct the exercise price of the ADS option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"ADSs subject to the option vest in equal quarterly installments over three years"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 3/A regulatory
"This Form 3/A is being filed to correct the exercise price"
An amended Form 3 (Form 3/A) is a corrected or updated disclosure filed with regulators that revises an insider’s initial report of their ownership in a public company — typically for officers, directors or large shareholders. Investors use it like a corrected inventory list: it clarifies who owns how many shares and whether earlier reports had errors, helping assess insider confidence, possible conflicts and the accuracy of ownership records that can affect stock valuation and trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What insider position does Kazia Therapeutics (KZIA) CEO John E. Friend II report?
He reports holding an option over 30,000 American Depositary Shares. The option gives him the right to buy ADSs at a fixed exercise price, subject to vesting conditions and an expiration date in July 2027.

What is the exercise price of the Kazia Therapeutics (KZIA) CEO’s ADS option?
The ADS option has an exercise price of $18.85 per American Depositary Share. This amended filing specifically corrects that exercise price compared with the prior report, clarifying the terms governing the CEO’s option grant.

How do the Kazia Therapeutics (KZIA) CEO’s ADS options vest over time?
The ADS option vests in equal quarterly installments over three years beginning April 22, 2024. Vesting depends on John E. Friend II maintaining a continuous service relationship with Kazia Therapeutics through each applicable vesting date.

When do the Kazia Therapeutics (KZIA) CEO’s ADS options expire?
The ADS option reported in this filing expires on July 22, 2027. After that expiration date, any unexercised portion of the option would no longer be exercisable under the disclosed terms of the grant.

What change is being made in this Kazia Therapeutics (KZIA) Form 3/A amendment?
This amended Form 3 is being filed to correct the exercise price of the ADS option granted on July 22, 2024. It updates the earlier disclosure so the recorded option terms now reflect the accurate $18.85 exercise price.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Friend John E. II
(Last)(First)(Middle)
THREE INTERNATIONAL TOWERS
LEVEL 24, 300 BARANGAROO AVE
(Street)
SYDNEY, NSWAUSTRALIA2000
(City)(State)(Zip)
AUSTRALIA
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
03/18/2026
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
American Depositary Share Option (Right to Buy) (1)07/22/2027American Depositary Shares(2)(3)30,000$18.85(4)D
Explanation of Responses:
1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 22, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 22, 2024.
2. Each ADS option is convertible into ADSs upon exercise.
3. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
4. This Form 3/A is being filed to correct the exercise price of the ADS option granted on July 22, 2024.
/s/ Jeffrey Bonacorda, Attorney-in-Fact04/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR